Efficacy of Lactobacillus Mucosae DPC6426 on Blood-lipids

A 12-week, Randomised, Double-blinded, Placebo Controlled Study to Evaluate the Efficacy of Lactobacillus Mucosae DPC6426 on Blood-lipids and Cholesterol in Healthy Mildly Hypercholesterolaemic (≥5.5mmol/L and <8 mmol/L) Adults

Cardiovascular disease (CVD) is the leading cause of death and morbidity in the EU. Among the recommendations to avoid heart disease is the maintenance of normal blood cholesterol levels, by ingesting a cardioprotective diet and if necessary via the use of drugs such as statins.

Low consumer compliance with dietary recommendations and the expense and side effects of drug therapy for many consumers, aligned with increased consumer acceptance of foods with additional health benefits has led to an opportunity for functional foods in the heart health area. The global market for foods with heart health benefits in the US, UK, Germany, France, Spain, Italy, Japan and Australia in 2009 was €10.84 billion (Leatherhead Food International).

In apilot study in 10 mildly hypercholesterolaemic (≥5mmol/L and <7.5mmol/L) male adults, who were administered Lb. mucosae DPC6426 daily for 6 weeks, resulted in an increase in ratio of HDL to total cholesterol from start to end of the study. Therefore, this Lactobacillus mucosae strain may lead to the development of novel functional foods and supplements with potential cardioprotective properties. Lb. mucosae DPC 6426 was benchmarked against plant sterol-esters, oat beta glucan and other probiotics strains (Lb. reuterii, NCIMB 30242) and was found to be more effective than oat beta glucan and Lb. reuterii, and similar in its effect on cholesterol as plant sterol esters.

Subjects were invited to participate in this study as they gad hypercholesterolaemia (defined as cholesterol between 5.5 mmol/L and 7.9 mmol/L)

The duration of your participation in this study is approximately 15-17 consecutive weeks.

Study Overview

• Status: Completed
• Conditions: Hypercholesterolaemia; Cholesterol
• Intervention / Treatment: Other: Lactobacillus mucosae DPC6426; Other: Placebo

• Study Type: Interventional
• Enrollment (Actual): 94
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Ireland
  • Co. Cork
    • Cork, Co. Cork, Ireland

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Be able to give written informed consen
2. Be between 20 and 70 years of age,
3. Subjects are mildly hypercholesterolaemic, with a total cholesterol level >5.5 mmol/L and <8mmol/L,
4. Subject has a BMI of between 18.5 - 32 Kg/m2,
5. Have a stable body weight (< 5% change) over the past 3-months, -Subject is in general good health as determined by the investigator.

Exclusion Criteria:

1. Are less than 20 and greater than 70 years of age,

2. Females are pregnant, lactating or wish to become pregnant during the study. Female subject is currently either of:

   • non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or any female who is surgically sterilized (via documented hysterectomy or bilateral tubal ligation). (For purposes of this study, postmenopausal is defined as one year without menses), OR
   • child bearing potential, the subject is eligible to enter and participate in this study if she is not lactating and has a negative urine pregnancy test at the screening visit, visit 2 and upon completion of the study at visit 7. The subject must also agree to one of the following methods of contraception: i. Complete abstinence from intercourse two weeks prior to administration of study drug, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the study medication in cases where subject discontinues the study prematurely. (Subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit.) or, ii. has a male sexual partner who is surgically sterilized prior to the Screen Visit and is the only male sexual partner for that subject or, iii. sexual partner(s) is/are exclusively female or, iv. Oral contraceptives (either combined or progestogen only) with double-barrier method of contraception consisting of spermicide with either condom or diaphragm. (Women of child-bearing potential using an oral contraceptive in combination with a double-barrier method of contraception are required to continue to use this form of contraception for 1 week following discontinuation of study medication), v. Use of double-barrier contraception, specifically, a spermicide plus a mechanical barrier (e.g. male condom, female diaphragm). The subject must be using this method for at least 1 week following the end of the study or, vi. Use of any intrauterine device (IUD) or contraceptive implant with published data showing that the highest expected failure rate is less than 1% per year. The subject must have the device inserted at least 2 weeks prior to the first Screen Visit, throughout the study, and 2 weeks following the end of the study.
3. Subject is a smoker,
4. Are hypersensitive to any of the components of the test product,
5. Have a significant acute or chronic, unstable and untreated disease or any condition which contraindicates, in the investigators judgement, entry to the study,
6. Subject is taking a probiotic or prebiotic product/supplement or have taken them within two weeks of the screening visit,
7. Subject has received a blood transfusion within the previous 6 months,
8. Subjects has taken antibiotics within the previous 3 months,
9. Subject has a history of drug and/or alcohol abuse at the time of enrolment,
10. Have a Gamma-GT outside the normal range,
11. Have an active gastrointestinal disorder or previous gastrointestinal surgery,

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lactobacillus mucosae DPC6426	Other: Lactobacillus mucosae DPC6426; Lactobacillus mucosae DPC6426
Sham Comparator: Placebo; an identical capsule without Lb. mucosae DPC6426.	Other: Placebo; an identical capsule without Lb. mucosae DPC6426.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total cholesterol	To compare the effect of Lactobacillus mucosae DPC6426, relative to placebo, on changes in total cholesterol, from baseline to week 12, in mildly hypercholesterolaemic (> 5.5 mmol/L and < 8mmol/L) adults.	Baseline to Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total cholesterol	To compare the effect of Lactobacillus mucosae DPC6426, relative to placebo, on changes in total cholesterol, from baseline to weeks 4 and 8, in mildly hypercholesterolaemic (> 5mmol/L and < 8mmol/L) adults	Baseline to Week 4 and Week 8
LDL-cholesterol	To compare the effect of Lactobacillus mucosae DPC6426, relative to placebo, on changes in LDL-cholesterol concentrations, from baseline to weeks 4, 8 & 12, in mildly hypercholesterolaemic (> 5mmol/L and < 8mmol/L) adults.	Baseline to Week 4, Week 8 and Week 12
HDL-cholesterol	To compare the effect of Lactobacillus mucosae DPC6426, relative to placebo, on changes in HDL-cholesterol concentrations, from baseline to weeks 4, 8 & 12, in mildly hypercholesterolaemic (> 5mmol/L and < 8mmol/L) adults.	Baseline to Week 4 Week 8 and Week 12
Triglycerides	To compare the effect of Lactobacillus mucosae DPC6426, relative to placebo, on changes in triglycerides concentrations, from baseline to weeks 4, 8 & 12, in mildly hypercholesterolaemic (> 5mmol/L and < 8mmol/L) adults.	Baseline to Week 4, Week 8 and Week 12
Adverse events	To evaluate the safety of Lactobacillus mucosae DPC6426, relative to placebo, in terms of the occurrence of adverse events in mildly hypercholesterolaemic (> 5.5mmol/L and < 8mmol/L) adults.	Baseline to Week 12

Collaborators and Investigators

• Sponsor: University College Cork
• Investigators: Principal Investigator: Prof. Noel Caplice, University College Cork

Study record dates

Study Major Dates

• Study Start (Actual): May 30, 2016
• Primary Completion (Actual): January 18, 2017
• Study Completion (Actual): January 18, 2017

Study Registration Dates

• First Submitted: April 2, 2026
• First Submitted That Met QC Criteria: April 2, 2026
• First Posted (Actual): April 9, 2026

Study Record Updates

• Last Update Posted (Actual): April 9, 2026
• Last Update Submitted That Met QC Criteria: April 2, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Nutritional and Metabolic Diseases; Hypercholesterolemia
• Other Study ID Numbers: AFCRO-059

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No